A South Oakland gene therapy company that suspended development work last week to consider operational alternatives is licensing its technology to a new startup that aims to treat an incurable disease.

NeuBase Therapeutics Inc. is licensing its treatment for Huntington’s disease to Helexva Inc., a startup with five part-time employees that doesn’t yet have a corporate office, CEO Dr. Robert Friedlander, chair, Department of Neurological Surgery at the University of Pittsburgh School of Medicine, said Monday. Huntington’s disease has been a research focus for Dr. Friedlander, a UPMC neurosurgeon, for 25 years.

“I’ve been on a mission to cure Huntington’s in humans,” he said. “I’m very passionate about this.”

In 1999, a research group led by Dr. Friedlander published the first study showing the slowing of Huntington’s progression in mice by blocking a specific protein. The treated mice lived 21% longer than untreated mice, which might have been the equivalent of adding one to ten years of life in humans.

Advertise with us

NeuBase was founded in 2009 by serial entrepreneur Dietrich Stephan, and became a publicly traded company in 2019 following a reverse merger with Ohr Pharmaceuticals. Mr. Stephan has founded or co-founded some 14 biotech companies and previously served as chair of the Department of Human Genetics at the University of Pittsburgh.

NeuBase is considering options that include an “acquisition, merger, business combination or other transaction,” according to an Aug. 3 release. Acknowledging the tough market for investment capital, Mr. Stephan said maximizing shareholder value was a priority and the company was “looking at all options.”

“The public markets for pre-market biotech companies are very difficult today,” he said. “As a result, the cost of capital is very high. This is very complex, high science. Funding it in this environment is very difficult.”

Such struggles are not unusual new life science companies, according to Evan Facher, vice chancellor, Innovation & Entrepreneurship at the University of Pittsburgh, especially in a city with a dearth of investment capital.

“We certainly don’t want to see this happen, but it is to be expected; it’s high risk, high reward,” Mr. Facher said. “We need a lot of these companies because only a small number will be successful. Our region is challenged because we don’t have enough shots on goal.”

Advertise with us

Huntington’s disease is caused by a single mutated gene that is inherited and causes a gradual breakdown and death of brain cells. Symptoms usually develop between the ages of 30 and 50, eventually including uncontrolled movement of the arms, legs, face and upper body and causing a characteristic dance-like gait.

No treatment slows or cures Huntington’s disease, which affects 30,000 people in the U.S., with another 200,000 at risk of becoming sick with the disorder.

Dr. Friedlander had partnered with NeuBase in a research project that he said had been making good progress using the company’s medicine as a treatment for Huntington’s when the company suspended operations.

“I found it incredibly appealing as a first in human’s treatment for Huntington’s,” he said about NeuBase’s medication. “We were making very nice progress with the new drug.”

Kris B. Mamula: kmamula@post-gazette.com